Treatment with broadly neutralizing influenza antibodies reduces severity of secondary pneumococcal pneumonia in mice
| Autor: | van Someren Gréve, Frank, van der Sluijs, Koenraad F., Tuip, Anita M., Schultz, Marcus J., de Jong, Menno D., Juffermans, Nicole P. |
|---|---|
| Přispěvatelé: | Medical Microbiology and Infection Prevention, ACS - Heart failure & arrhythmias, Graduate School, Intensive Care Medicine, AII - Infectious diseases, ACS - Diabetes & metabolism, ACS - Pulmonary hypertension & thrombosis, ACS - Microcirculation |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Male
Antibodies Viral influenza virus murine model Influenza Human AT10_002 Animals Humans Immunologic Factors Research Articles broadly neutralizing antibodies Influenza A Virus H3N2 Subtype Body Weight Immunization Passive Pneumonia Pneumococcal Viral Load Bacterial Load respiratory tract diseases Mice Inbred C57BL secondary infections Disease Models Animal Streptococcus pneumoniae Treatment Outcome Cytokines Bronchoalveolar Lavage Fluid Research Article |
| Zdroj: | Journal of Medical Virology Journal of medical virology, 90(9), 1431-1437. Wiley-Liss Inc. |
| ISSN: | 1096-9071 0146-6615 |
| Popis: | Secondary bacterial pneumonia is a frequent complication of influenza, associated with high morbidity and mortality. We hypothesized that treatment with neutralizing influenza A antibody AT10_002 protects against severe secondary pneumococcal infection in a mouse model of influenza A infection. Influenza A (H3N2) virus–infected male C57Bl6 mice were treated intravenously with either AT10_002 or a control 2 days postinfection. Seven days later, both groups were infected with Streptococcus pneumoniae and killed 18 hours later. Mice receiving AT10_002 showed less loss of bodyweight compared with controls (+1% vs −12%, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text